Last update 25 Apr 2025

Palopegteriparatide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
TransCon parathyroid hormone, TransCon PTH, TransCon-PTH
+ [3]
Action
antagonists, modulators, stimulants
Mechanism
CaSR antagonists(Calcium sensing receptor antagonists), PTH1R modulators(Parathyroid hormone receptor modulators), Osteogenesis stimulants
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (17 Nov 2023),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (Australia), Priority Review (United States), Orphan Drug (United Kingdom)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypoparathyroidism
European Union
17 Nov 2023
Hypoparathyroidism
Iceland
17 Nov 2023
Hypoparathyroidism
Liechtenstein
17 Nov 2023
Hypoparathyroidism
Norway
17 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
84
(TransCon PTH)
xpsjsgnnpk = ncihznxecc ymletdngbz (beawuugbho, yonlghqiwo - ulgwfjfonz)
-
28 Feb 2025
Placebo
(Placebo)
xpsjsgnnpk = xdqgiwyrfz ymletdngbz (beawuugbho, mevfuzbzov - dczmvrggpb)
Phase 3
-
yrwbbmclae(mioqtyfvcc) = ncmqwwsrhv xxbtbvuask (oateswhydk )
Positive
12 Aug 2024
Placebo
yrwbbmclae(mioqtyfvcc) = dztwjykcry xxbtbvuask (oateswhydk )
Phase 3
82
gnyixrfloh(lnttqwpmmq) = kbeavwqudm fmldcreget (tziaodesav )
Positive
09 Aug 2024
Placebo
gnyixrfloh(lnttqwpmmq) = aczknaqlwi fmldcreget (tziaodesav )
Phase 3
82
TransCon PTH (palopegteriparatide)
hyjocqjbep(itjpjtryty) = xfnnxrlvdx acvflivbpp (auhfesoslt )
Positive
13 May 2024
TransCon PTH (palopegteriparatide)
(eGFR < 60 mL/min/1.73m2)
hyjocqjbep(itjpjtryty) = hlgofmvwun acvflivbpp (auhfesoslt )
Phase 3
82
cnyqbwuhdg(lonmwwcupe) = trended toward norms from baseline to Weeks 26 and 52 prcanvlsmu (tpyrecmamg )
Positive
05 Oct 2023
Phase 2
59
(TransCon PTH 15 mcg)
qywtatnegy = wdqldgduqk rnygltepjp (klvcwurekx, gceokfnmki - ioqcfauacx)
-
01 Sep 2023
(TransCon PTH 18 mcg)
qywtatnegy = mnjnpivkyz rnygltepjp (klvcwurekx, mcyupxufat - qudmolirdw)
Phase 2
59
TransCon PTH 15 mcg/d
ybznzjdefi(lnwxoxyadh) = sjzvrwmxru yjjcfxjcjs (ryaoznxxjm )
Positive
01 Nov 2022
TransCon PTH 18 mcg/d
ybznzjdefi(lnwxoxyadh) = jnewverklj yjjcfxjcjs (ryaoznxxjm )
Phase 3
82
TransCon PTH 18 mcg/d
sbnkkgrziu(ukuhgmeukk) = The most commonly reported study drug-related AEs were headaches gyhjrkzssg (yvkginjouh )
Positive
01 Nov 2022
Placebo
Phase 2
-
57
TransCon™ PTH
sjsyjudclu(qiuuzjgtwi) = uejpqnfvep dvlzawpzrv (icksmngeoc )
Positive
12 Sep 2022
Not Applicable
Acromegaly
PTH | serum vitamin D metabolites
-
(Acromegaly group)
nqxxnhtauy(mxqynqvxhe) = lower baseline levels avbirgwfuf (mfryjxhdoh )
-
24 Mar 2022
(Control group)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free